Table 1 |
|||
|
Clinical findings in patients with myeloid sarcoma |
|||
|
Case |
Age, year/sex |
Site |
Bone marrow |
|
|
|||
|
1 |
25/M |
Scrotum |
Uninvolved |
|
2 |
66/M |
Kidney |
RAEB-2* |
|
3 |
27/M |
Testis |
AML, M2 |
|
4 |
54/F |
Colon |
AML, M2 |
|
5 |
58/M |
Orbit |
Uninvolved |
|
6 |
72/M |
Skin |
Uninvolved |
|
7 |
46/F |
Lymph Node |
Uninvolved |
|
8 |
62/F |
Gingiva |
Myelofibrosis |
|
9 |
36/F |
Vagina |
AML, M1 |
|
10 |
38/M |
T5, T7 |
CML/BP** |
|
11 |
51/F |
Gallbladder |
AML, M5b |
|
12 |
40/F |
Breast |
AML, M1 |
|
13 |
38/F |
Breast |
AML, M4 |
|
|
|||
|
*RAEB-2: Refractory anemia with excess blasts 2 **CML/BP: Chronic myelogeneous leukemia, blast phase |
|||
|
Alexiev et al. Diagnostic Pathology 2007 2:42 doi:10.1186/1746-1596-2-42 |
|||
